BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 16423429)

  • 21. Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy.
    Lu CL; Hung CC; Chuang YC; Liu WC; Su CT; Su YC; Chang SF; Chang SY; Chang SC
    Hum Vaccin Immunother; 2013 Feb; 9(2):398-404. PubMed ID: 23291936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination.
    Madhi SA; Klugman KP; Kuwanda L; Cutland C; Käyhty H; Adrian P
    J Infect Dis; 2009 Apr; 199(8):1168-76. PubMed ID: 19265481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Opsonic function of bronchoalveolar lavage IgG after pneumococcal vaccination in HIV-infected and uninfected adults.
    Tam JC; Grant NL; Freire-Moran L; Tolmie H; French N; Gordon SB
    J Allergy Clin Immunol; 2009 Jun; 123(6):1420-1. PubMed ID: 19423153
    [No Abstract]   [Full Text] [Related]  

  • 24. Conjugate and polysaccharide pneumococcal vaccines do not improve initial response of the polysaccharide vaccine in HIV-infected adults.
    Peñaranda M; Payeras A; Cambra A; Mila J; Riera M;
    AIDS; 2010 May; 24(8):1226-8. PubMed ID: 20299956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunological responses to pneumococcal vaccine in frail older people.
    Ridda I; Macintyre CR; Lindley R; Gao Z; Sullivan JS; Yuan FF; McIntyre PB
    Vaccine; 2009 Mar; 27(10):1628-36. PubMed ID: 19100304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998--2003.
    Teshale EH; Hanson D; Flannery B; Phares C; Wolfe M; Schuchat A; Sullivan P
    Vaccine; 2008 Oct; 26(46):5830-4. PubMed ID: 18786586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.
    Glesby MJ; Watson W; Brinson C; Greenberg RN; Lalezari JP; Skiest D; Sundaraiyer V; Natuk R; Gurtman A; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    J Infect Dis; 2015 Jul; 212(1):18-27. PubMed ID: 25395187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of sequential pneumococcal vaccination in subjects splenectomised for hereditary spherocytosis.
    Stoehr GA; Rose MA; Eber SW; Heidemann K; Schubert R; Zielen S
    Br J Haematol; 2006 Mar; 132(6):788-90. PubMed ID: 16487181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of immunologic parameters and HIV RNA in relation to humoral pneumococcal polysaccharide vaccine responses in patients with HIV infection.
    Kvale D; Aaberge IS; Frøland SS
    Eur J Clin Microbiol Infect Dis; 2002 Sep; 21(9):688-90. PubMed ID: 12373505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-infected pregnant women and kinetics of passively acquired antibodies in young infants.
    Almeida Vde C; Mussi-Pinhata MM; De Souza CB; Kubo CA; Martinez EZ; Carneiro-Sampaio MM; Duarte G
    Vaccine; 2009 Jun; 27(29):3856-61. PubMed ID: 19443091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Immunological effect of vaccination against pneumococcal infection in HIV-infected children].
    Pakhomov DV; Kostinov MP; Poddubikov AV; Vaneeva NP; Snegova NF; Nikitina TN; Zinkina TN; Suloeva SV
    Zh Mikrobiol Epidemiol Immunobiol; 2009; (2):48-52. PubMed ID: 19459477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of current joint American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma and Immunology guidelines for antibody response to the 23-valent pneumococcal vaccine using a population of HIV-infected children.
    Kamchaisatian W; Wanwatsuntikul W; Sleasman JW; Tangsinmankong N
    J Allergy Clin Immunol; 2006 Dec; 118(6):1336-41. PubMed ID: 17157665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoglobulins and immunogenicity of pneumococcal vaccination in preschool asthma.
    Rose MA; Schubert R; Kujumdshiev S; Kitz R; Zielen S
    Int J Clin Pract; 2006 Nov; 60(11):1425-31. PubMed ID: 17073839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003].
    Jacomet C; Lesens O; Villemagne B; Darcha C; Tournilhac O; Henquell C; Cormerais L; Gourdon F; Peigue-Lafeuille H; Travade P; Beytout J; Laurichesse H
    Med Mal Infect; 2006 Mar; 36(3):157-62. PubMed ID: 16503104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV-infected adults in the era of highly active antiretroviral therapy: analysis stratified by CD4 T-cell count.
    Song JY; Cheong HJ; Noh JY; Choi MJ; Yoon JG; Kim WJ
    Hum Vaccin Immunother; 2020; 16(1):169-175. PubMed ID: 31441710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children.
    King JC; Vink PE; Farley JJ; Parks M; Smilie M; Madore D; Lichenstein R; Malinoski F
    Pediatr Infect Dis J; 1996 Mar; 15(3):192-6. PubMed ID: 8852905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization.
    Cohen AL; Harrison LH; Farley MM; Reingold AL; Hadler J; Schaffner W; Lynfield R; Thomas AR; Campsmith M; Li J; Schuchat A; Moore MR;
    AIDS; 2010 Sep; 24(14):2253-62. PubMed ID: 20671543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.